Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy

Epidemiol Infect. 2005 Aug;133(4):687-93. doi: 10.1017/s0950268805003936.

Abstract

We evaluated whether the increased immunogenicity provided by an MF59-adjuvant influenza vaccine translates into increased protection among the elderly. Residents of 25 long-term care facilities received either the adjuvant or a non-adjuvant vaccine. The odds ratios (OR) of influenza-like illness were calculated for non-adjuvant vs. adjuvant vaccine recipients, also stratifying for chronic cardiovascular, respiratory, and renal diseases. The risk was higher for the non-adjuvant vaccine recipients and highest for those with respiratory disease (OR 2.27, 95% CI 1.09-4.82) and cardiovascular disease (OR 1.88; 95% CI 1.31-2.72). In this study the MF59-adjuvant vaccine provided superior clinical protection among the elderly, especially those with chronic diseases.

Publication types

  • Comparative Study

MeSH terms

  • Adjuvants, Immunologic / administration & dosage*
  • Age Distribution
  • Aged
  • Aged, 80 and over
  • Cohort Studies
  • Confidence Intervals
  • Female
  • Follow-Up Studies
  • Homes for the Aged*
  • Humans
  • Immunization Schedule
  • Incidence
  • Influenza Vaccines / administration & dosage*
  • Influenza, Human / epidemiology
  • Influenza, Human / prevention & control*
  • Italy / epidemiology
  • Long-Term Care
  • Male
  • Nursing Homes*
  • Odds Ratio
  • Polysorbates / administration & dosage*
  • Risk Factors
  • Sensitivity and Specificity
  • Sex Distribution
  • Squalene / administration & dosage*
  • Squalene / immunology

Substances

  • Adjuvants, Immunologic
  • Influenza Vaccines
  • MF59 oil emulsion
  • Polysorbates
  • Squalene